STAT

The basics: What we know — and don’t know — about the virus spreading in China and beyond

News about the coronavirus spreading in China and beyond is coming fast. Here's a breakdown on what we know — and don't know — so far.
A woman wears a mask while at the subway station in Wuhan, China.

It’s been only three weeks since Chinese authorities alerted the World Health Organization that it had an outbreak of unusual pneumonia cases. An astonishing amount of information has been learned in the days since about the outbreak, caused by a new virus that jumped from animals into people. But a frustrating amount of information remains still beyond our grasp.

Scientists and public health officials in China and beyond are scrambling to try to learn more about the virus, which has already spread out from the Chinese city of Wuhan, where the outbreak appears to have started, to other parts of China and several other countries, including the United States

We all have more questions than answers. But here’s some of what we’ve learned about this new disease threat. 

Where did the virus come from? 

Health officials in China tracked many of the initial cases to a large seafood market in Wuhan, a city in central China, that also sold wild animals as meat. The leader of an expert committee working on the outbreak has said some type of game is the most

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks